Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
Stocks · News reference
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions'
The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
Global Skin Care Products Market is Expected to Surpass the USD 260 Billion Mark by 2034 | DelveInsight
The global skin care products market is projected to grow from USD 166 billion in 2025 to USD 262 billion by 2034, with a CAGR of approximately 5%. Growth is driven by rising consumer awareness of skin health, increasing disposable incomes, demand for premium and personalized products, and the influence of social media trends. Asia-Pacific leads with 38% market share, while North America is the fastest-growing region. Key players include L'Oréal, Unilever, Procter & Gamble, and Estée Lauder.
This Consumer Staples Giant's Dividend Streak Rivals PepsiCo. Nobody Talks About It.
Kimberly-Clark is an overlooked Dividend King with a 54-year consecutive dividend increase streak matching PepsiCo's. Despite lower brand recognition, KMB offers a higher yield (4.7% vs 4.1%), more resilient demand for household products, and is acquiring Kenvue to enhance its global portfolio, making it an attractive option for income-focused investors.